Schrodinger shares fall 3.44% premarket after discontinuing SGR-2921 clinical development.

Schrodinger, Inc. declined 3.44% in premarket trading, following the company's announcement to discontinue the clinical development program for SGR-2921, its CDC7 inhibitor. The decision was made due to two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, making the path to development as a combination therapy difficult to pursue.